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malaria antigens than aparasitaemic immune indi- 
viduals might imply that antigen-specific T-cells play 
a role in the development of sterile immunity in 
malaria. 
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Further trials of a vaccine against American 
cutaneous leishmaniasis 
We have continued studies on a vaccine against 
American cutaneous leishmaniasis (MAYRINK et al., 
1978, 1979, 1985) by carrying out two controlled; 
double-blind field trials. The trials were conducted at 
Manaus, State of Amazonas, Brazil, in 1981 and 1983. 
The participants were ll-year-old healthy males, 
army conscripts serving in Comando Militar da 
Amazonia (CMA). The conscripts were randomly 
assigned to- vaccine or placebo- groups, and were 
followed UD for 12 months. The vaccine and Mon- 
tenegro anhgen were prepared in the manner pre- 
viously described, using the same stocks of Leish- 
mania. The placebo was phosphate buffer pH 7-4 plus 
merthiolate 1: 10,000. 
In the 1981 trial, only 33% of the vaccinated group 
converted their responses to Montenegro antigen 
within 35 davs. The low conversion rate is attributed 
to the fact thHt the experimental vaccine was adminis- 
tered during the period that participants also received 
yellow fever, typhus and tetanus inoculations. At the 
end of 12 months, the incidence of leishmaniasis 
amongst hose with changed responses to Montenegro 
antigen was 67.3% lower than that of the placebo 
group. 
In the 1983 trial, conscripts received yellow fever 
vaccine 120 davs before the exnerimental leish- 
maniasis vaccinh was administered. Changes in re- 
sponse to Montenegro antigen occurred in 68% of the 
vaccinated group and the annual incidence of the 
disease was 85.7% lower than that of the placebo 
group. 
Full details of the two field trials will be published 
elsewhere. 
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Absence of pharmacokinetic interaction between 
Fansida? and mefloquine 
The ever-growing resistance of plasmodia, particu- 
larly Plasmodium falciparum, against chloroquine or 
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other commonly used antimalarials is a big problem 
today. Newly developed drugs are also likely to 
induce, with time, resistant forms of the parasite. It 
has been suggested that this process might be slowed 
down by the use of combination preparations (PETERS 
& ROBINSON 
FansimefR, 
1984; MERKLI et al., 1980). 
a combination of FansidarR 
(= sulphadoxine + pyrimethamine) and mefloquine, 
produced remarkable cure rates in the treatment of 
falciparum malaria resistant to chloroquine (EKUE et 
al.. 1985: TIN et al.. 1985: HARINASUTA et al.. 19851. 
Both pyrimethamine and sulphadoxine showa very 
long half-life so that their potentiating effects persist 
for a long time. The addition of mefloquine might 
lead to kinetic interactions which have not previously 
been studied. 
The pharmacokinetic haracteristics of the Fan- 
simep combination have been compared to those of 
Fansidara and mefloquine administered alone. Heal- 
thy human volunteers received orally and se 
one dose of Fansidara, one dose of Fansime 
uentially 
8 and one 
dose of mefloquine. Intervals of four weeks and six 
months were left between the first and second, and 
between the second and third, applications, respec- 
tively. The plasma levels of the components present in 
each of the three preparations administered were 
measured and their pharmacokinetic parameters de- 
termined using TOPFIT or NONLIN programs 
based on a two compartment model. The pharmaco- 
kinetic parameters t,, C,, tY$, AUC$ syste- 
mic clearance and apparent volume of distribution 
were practically unchanged for all three components 
whether FansidarR or mefloauine were administered 
alone or together in the form of FansimeP. On 
average, a slight increase in AUC (13%) was observed 
for mefloquine. This difference, however, was not 
significant (t-test : 0.5>p>O-3). It is noteworthy that 
the degree of binding of the single components to 
human plasma proteins was virtually unmodified by 
the simultaneous administration of the two other 
partners, and that multiple dose kinetics of FansimeP 
produced steady-state plasma levels in the range of 
those predicted from single dose kinetics. The avail- 
able evidence, therefore, indicates the absence of 
interaction between the components of the FansimeP 
combination in man. 
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Leishmuniu infuntum, causative organism of visceral 
leishmaniasis at Biskra (Algeria) 
Infantile visceral eishmaniasis i  kn<wn to occur in 
northern Algeria in a geographical area correspond- 
inn to the sub-humid bioclimatic zone (BELAZZOUG 
et al., 1985). However, the 21 cases diagnosed uring 
the last 10 years at Biskra in southern Algeria 
corresponding to the arid bioclimatic zone remained 
until recently an epidemiological mystery. This area is 
an important focus of zoonotic cutaneous leish- 
maniasis caused by Leishmuniu mujor (see BELAZ- 
ZOUG, 1984). Hence, we were tempted to think that 
L. major might be the causative organism as suggested 
bv SCHNUR et al. (1985) for infantile kala-azar at El 
Agamy in Egypt,‘ an area ecologically similar to 
Biskra. 
We isolated three stocks from children presenting 
kala-azar. who originated from Biskra and who had 
never left this area:The isoenzyme identification (two 
stocks by Prof. J. A. Rioux from Montpellier, and one 
by Dr. D. A. Evans from London) revealed L. 
infuntum. 
We conducted a sero-epidemiological enquiry using 
indirect immunofluorescence and found eight dogs 
positive out of 102. An isolate from one of these dogs 
has been isoenzymically identified as L. infanturn. 
It appears, therefore, that visceral leishmaniasis in 
this area is identical to that of northern Algeria with 
L. infanturn as the cause, the dog as reservoir and 
probably Phlebotomus perniciosus or P. longicuspis, 
known to be present in this area (DEDET et al., 1984), 
as vector. P. longicuspis, first considered to be a 
variety of P. lungeroni by NITZULESCU (1930), seems 
to be a more suitable vector as it is well adapted to the 
climatic conditions of Biskra (PARROT & CLASTRIER, 
1956). 
Our tiding strongly supports KILLICK-KEN- 
DRICK’S view (1985) that L. infuntum is the causative 
organism of kala-azar at El Agamy in Egypt and P. 
langeroni the possible vector. 
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